GLP-1 drugs and dry eye disease in type 2 diabetes
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests whether a diabetes and weight-loss medication called GLP-1 receptor agonists affects dry eye disease. Researchers want to see if this medication helps or worsens dry eyes in people with type 2 diabetes and obesity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have never taken GLP-1 receptor agonist medications before (such as semaglutide, tirzepatide, or similar drugs)
- You are not pregnant or breastfeeding
- You have not had serious low blood sugar episodes multiple times in the past 2 years
- You do not have active eye inflammation or infection (pink eye, corneal infection, or immune-related eye inflammation)
- You have not had cataract surgery or retina surgery in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people who have gum disease (periodontitis) are more likely to have dry eye disease. If you have both conditions, taking part could help doctors understand how they might be connected and improve care.
This trial tests a new eye drop called DFL24498 to see if it helps people with dry eye disease. You may qualify if your dry eye is moderate to severe and other treatments haven't worked well for you.
This study tests an eye drop called lifitegrast for people with dry eye disease. It looks at whether the drops can improve eye comfort, reduce dryness, and help eye surface health. You may be able to join if you have had dry eye symptoms and used artificial tears in the past month.
This study tests whether over-the-counter lubricating eye drops can improve dry eye symptoms and eye comfort. It compares the drops to no treatment to see how well they work.
This trial tests a special eyelid massage device to see if it helps people with dry eye caused by blocked oil glands in the eyelids. It may improve symptoms and eye comfort.
This study compares two types of diabetes medications (GLP-1 receptor agonists and SGLT2 inhibitors) to see how they affect blood vessels in the back of the eye over time. It may help doctors understand if one drug is better for protecting your eyes.
Hear when a new Dry Eye Disease (DED) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.